Fiduciary Alliance LLC Has $3.70 Million Stock Position in Pfizer Inc. $PFE

Fiduciary Alliance LLC boosted its holdings in Pfizer Inc. (NYSE:PFE) by 46.4% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 145,263 shares of the biopharmaceutical company’s stock after purchasing an additional 46,043 shares during the quarter. Fiduciary Alliance LLC’s holdings in Pfizer were worth $3,701,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of PFE. Capital Advisory Group Advisory Services LLC increased its stake in shares of Pfizer by 2.9% in the 2nd quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company’s stock valued at $328,000 after acquiring an additional 388 shares in the last quarter. Citizens National Bank Trust Department grew its holdings in Pfizer by 0.9% in the second quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company’s stock worth $1,118,000 after purchasing an additional 395 shares during the period. Peak Asset Management LLC increased its stake in Pfizer by 1.4% in the second quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock valued at $697,000 after purchasing an additional 402 shares in the last quarter. Able Wealth Management LLC raised its holdings in shares of Pfizer by 2.0% during the second quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company’s stock valued at $512,000 after purchasing an additional 413 shares during the period. Finally, Boltwood Capital Management boosted its position in shares of Pfizer by 0.7% during the 3rd quarter. Boltwood Capital Management now owns 58,274 shares of the biopharmaceutical company’s stock worth $1,485,000 after purchasing an additional 420 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Down 1.9%

Shares of Pfizer stock opened at $25.05 on Thursday. The company has a market capitalization of $142.43 billion, a P/E ratio of 14.56 and a beta of 0.46. The stock has a fifty day simple moving average of $25.09 and a 200 day simple moving average of $24.82. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $27.69. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The firm had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio is presently 100.00%.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $30.00 target price on shares of Pfizer in a research report on Friday, October 31st. Morgan Stanley cut their target price on Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a report on Friday, December 12th. Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Wednesday. Finally, HSBC reaffirmed a “buy” rating and issued a $29.00 price objective on shares of Pfizer in a research note on Wednesday, December 10th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Pfizer has an average rating of “Hold” and an average price target of $28.06.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.